New drug trial offers hope for Tough-to-Treat lung cancer
Disease control
Recruiting now
This study is testing a new drug called STK-012 for people with advanced non-small cell lung cancer and other solid tumors. Researchers want to see if STK-012 works better when given alone or combined with standard cancer treatments. The trial will involve about 364 participants …
Phase: PHASE1, PHASE2 • Sponsor: Synthekine • Aim: Disease control
Last updated Apr 01, 2026 21:56 UTC